Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy.

Science China. Life sciences - 1 Jun 2025

Zhou Linghui, Feng Youqin, Hong Ruimin, Wei Guoqing, Zhang Mingming, Chang Alex H, Huang He, Hu Yongxian

Abstract excerpt

Despite advancements in CAR-T therapy, over half of the lymphoma patients still face drug resistance or relapse. Seventy-nine Chinese patients with B-cell lymphoma provided 192 serum samples for circulating tumor DNA (ctDNA) detection to identify the genomic features linked to prognosis during CAR-T cell therapy. Patients in complete remission and noncomplete remission groups were analyzed, and those with >10...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to East Asian People

Share to Genomics

Share to Immunotherapy, Adoptive

Share to Lymphoma, B-Cell

Share to Receptors, Chimeric Antigen

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 40189492
DOI: 10.1007/s11427-024-2783-2

Genes

TP53
APC
BCR
BTG2
CARD11
CBLB
CDKN2A
FAT1
FOXO1
KMT2D
MUC16
MYD88
PDGFRB
SPEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy.PMID 40189492Read ↗

Integrating genomic features for prognosis in Chinese patients with diffuse large B-cell lymphoma following R-CHOP therapy.Semantic proximity Read ↗

[Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].Semantic proximity Read ↗

Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.Semantic proximity Read ↗

Comprehensive Pan-Cancer Analysis and the Regulatory Mechanism of ASF1B, a Gene Associated With Thyroid Cancer Prognosis in the Tumor Micro-EnvironmentSemantic proximity Read ↗

Genomic Landscape and Molecular Subtypes of Primary Central Nervous System LymphomaSemantic proximity Read ↗

Genomic landscape and molecular subtypes of primary central nervous system lymphoma.Semantic proximity Read ↗

Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patientsSemantic proximity Read ↗

Individualized ctDNA Fingerprints to Monitor Treatment Response and Recurrence in Multiple Cancer TypesSemantic proximity Read ↗

Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling.Semantic proximity Read ↗

TP53 and KMT2D mutations associated with worse prognosis in peripheral T-cell lymphomas.Semantic proximity Read ↗

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.Semantic proximity Read ↗

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.